February 4th Aphria Deadline: Bernstein Liebhard LLP

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
34
February 4th Aphria Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Aphria Inc. – APHA

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important February 4, 2019 lead plaintiff deadline in the shareholder class action lawsuit against Aphria Inc. (“Aphria” or the “Company”) (NYSE: APHA). The lawsuit seeks to recover damages on behalf of those who purchased the securities of Aphria between July 17, 2018 and December 4, 2018, both dates inclusive (the “Class Period”).

If you purchased Aphria securities, and/or would like to discuss your legal rights and options, please visit  Aphria Shareholder Class Action Lawsuit  or contact Daniel Sadeh toll free at (877) 779-1414 or  dsadeh@bernlieb.com .

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Latin American assets acquired by the Company lacked adequate licenses to operate and were overvalued; (2) the acquisition of the Latin American assets would enrich the Company’s CEO and other insiders at the expense of shareholders; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

On December 3, 2018, Quintessential Capital Management and Hindenburg Research published a report alleging, among other things, that the Company’s recent acquisitions in Latin America were part of a series of transactions designed to enrich Company insiders and that these acquisitions lacked established operations and/or licenses to operate in the cannabis industry.

On this news, Aphria’s stock fell $1.85 per share or approximately 23% to close at $6.05 per share on December 3, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than February 4, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Aphria securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/aphria-inc-aph...-stock-99/ or contact Daniel Sadeh toll free at (877) 779-1414 or  dsadeh@bernlieb.com .

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information Daniel Sadeh Bernstein Liebhard LLP http://www.bernlieb.com (877) 779-1414 dsadeh@bernlieb.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 44

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

KPN Achieves Impressive Growth; Forecast for 2025 Enhanced

Updated Category News Views 271

KPN Achieves Remarkable Growth in Q2 2025 KPN has recently demonstrated a strong performance in the second quarter of 2025, showcasing impressive growth across various segments. The company reported a year-on-year growth of 3.7% in service revenues, a testament to its robust business strategy and market position. Consumer Service Revenue Gains The consumer segment has...

Continue Reading
Socket Mobile's Financial Trends Show Promise for Future Growth

Updated Category News Views 66

Socket Mobile Reports Q3 Financial Results Socket Mobile, Inc. (NASDAQ: SCKT), a prominent name in the field of data capture and delivery solutions, recently disclosed its financial results for the third quarter of 2024, presenting notable shifts in revenue and product adoption. The company emphasizes its commitment to enhancing productivity through innovative...

Continue Reading
Sapiens Recognized for Outstanding Software Solutions Excellence

Updated Category News Views 220

Sapiens UnderwritingPro Achieves Recognition for Excellence Sapiens International Corporation has once again made waves in the insurance industry with its advanced UnderwritingPro solution. Renowned for driving efficiency and automation, the software provides comprehensive functionality that benefits insurers across various sectors. Honored with the XCelent Award...

Continue Reading
Opportunity for LAZR Investors: Join the Class Action Today

Updated Category News Views 175

Investing in Luminar Technologies: What You Need to Know For those invested in Luminar Technologies, Inc. (NASDAQ: LAZR), important news is unfolding regarding a recent class-action lawsuit that has potential implications for shareholders. The Rosen Law Firm, a reputable entity in securities law, has issued a reminder for investors who purchased Luminar securities during...

Continue Reading
Celebrating HVAC Techs: Behind-the-Scenes Heroes

Updated Category News Views 8

Recognizing the Unsung Heroes of Home Comfort Let's face it, HVAC techs don't always get the recognition they deserve. On National HVAC Technician Day, June 22, Bacon Plumbing Heating Air Electric took a moment to shine a light on those skilled folks keeping homes comfy year-round across the Dallas-Fort Worth Metroplex. You know, the folks who swoop in just in time during...

Continue Reading